Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi paid $425 million upfront — $300M cash plus $125M equity — to expand its 2018 mRNA collaboration with Translate Bio to cover the entire infectious…
Sanofi has dramatically expanded its mRNA vaccine collaboration with Translate Bio, agreeing to pay $300 million in cash plus $125 million in equity to broaden…
Sanofi today announced an agreement to acquire its mRNA vaccine partner Translate Bio for $38 per share in cash, valuing the deal at approximately…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Sanofi Pasteur and Translate Bio closed an expanded collaboration and licensing agreement covering mRNA vaccines for all infectious diseases (broadening the 2018 deal that had covered up to five pathogens). Translate Bio received $425M ($300M cash upfront + $125M equity) with eligibility for up to $1.9B in milestones plus tiered royalties. The collaboration proved the foundation for Sanofi's full acquisition of Translate Bio: announced Aug 3, 2021 at $38/share (~$3.2B equity value) and completed Sep 14, 2021. Sanofi subsequently deprioritized the COVID-19 candidate MRT5500 and pivoted the Translate Bio mRNA platform toward seasonal influenza and other pathogens; the seasonal-flu mRNA effort was later wound down.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Translate Bio Inc. (this deal) | 2020 | $2.3B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2020 deals · Sanofi SA deals · Infectious Disease deals